Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2026 15:15 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin...
April 17, 2026 15:00 ET | Source: Pheast Therapeutics

Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026

Initial clinical data highlight a differentiated safety and pharmacologic profile for PHST001, including target engagement, innate immune activation, and early signals of clinical activity ...
April 17, 2026 15:00 ET | Source: Zymeworks Inc.

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable...
April 17, 2026 15:00 ET | Source: Asgard Therapeutics

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Asgard Therapeutics to present a poster on its lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026.
April 16, 2026 03:00 ET | Source: STORM Therapeutics

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

STORM Therapeutics announces a $56 million Series C financing to support the advancement of STC-15 in a Phase 2 study.
April 15, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in...
April 15, 2026 08:08 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy

Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC:...
April 14, 2026 08:00 ET | Source: Clairity, Inc.

Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods

Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35 BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Clairity, Inc. announces the National...
April 14, 2026 08:00 ET | Source: GeneCentric Therapeutics Inc

GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026

GeneCentric will present new data on its fragmentomics-based ExpressCT™ liquid biopsy technology at AACR 2026.
April 14, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...